{"schema_version":"secwatch.filing_event.v1","accession":"0001570562-26-000079","form_type":"8-K","ticker":"EOLS","cik":"0001570562","company_name":"Evolus, Inc.","filed_at":"2026-07-08T13:03:46+00:00","discovered_at":"2026-07-08T13:05:00.256971+00:00","generated_at":"2026-07-08T13:05:06.249518+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Evolus licenses Profhilo for U.S. skin-quality market; no upfront payment","bullets":["Exclusive license to develop and commercialize Profhilo in the U.S. for aesthetics and dermatology.","No upfront or milestone payments; economics via transfer-price model supporting target gross margins.","Evolus responsible for U.S. development and FDA approval; initial term 15 years from first approval.","Profhilo has 4.8M+ treatments globally since 2015; market leader in European injectable skin quality.","Agreement does not affect 2026 revenue/opex/operating profit outlook or 2028 targets."],"urls":{"canonical":"https://secwatch.observer/filing/0001570562-26-000079","json":"https://secwatch.observer/filing/0001570562-26-000079.json","markdown":"https://secwatch.observer/filing/0001570562-26-000079.md","text":"https://secwatch.observer/filing/0001570562-26-000079.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/0001570562-26-000079-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000079/eols-20260707.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-08T13:05:06.249518+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}